Microbiology SpectrumMicrobiologyPeer-reviewed journal article
Mutations in ampD cause hyperproduction of AmpC and CphA beta-lactamases and high resistance to beta-lactam antibiotics in Chromobacterium violaceum
Luís Gustavo LaranjeiroiD, Carlos Eduardo Milani Neme, Maristela Previato-MelloiD, Bianca B. BatistaiD, Isabel S. HenriquesiD, José F. da Silva NetoiD
Abstract
Bacterial resistance to beta-lactam antibiotics mediated by beta-lactamase enzymes is widespread worldwide. Chromobacterium violaceum, an environmental Gram-negative bacteria pathogen, is intrinsically resistant to some beta-lactam antibiotics. In this work, we found that mutations in an ampD gene, encoding a peptidoglycan-recycling amidase, cause hyperproduction of two chromosomal beta-lactamases (AmpC and CphA), conferring high beta-lactam resistance in C. violaceum. Susceptibility tests using {Delta}ampC, {Delta}cphA, and{Delta} ampC{Delta}cphA mutant strains revealed specific susceptibility profiles to penicillin, cephalosporin, and carbapenem beta-lactams, suggesting that AmpC is a broad-spectrum beta-lactamase (penicillinase and cephalosporinase), while CphA is a narrow-spectrum metallo-carbapenemase. Beta-galactosidase assays indicate that the expression of ampC and cphA increased in response to beta-lactams. We isolated C. violaceum spontaneous mutants resistant to the antibiotic ceftazidime and found that most mutants were also resistant to several other beta-lactams and overexpressed ampC and cphA. DNA sequencing of the three paralog genes encoding the C. violaceum AmpD amidases revealed mutations of different types in AmpD1 (CV_0566) in most of the spontaneous mutants, but no mutation was found in AmpD2 or AmpD3. Analysis of single and combined null amidase mutants revealed overexpression of both beta-lactamases and increased resistance to beta-lactams only in mutants with deleted ampD1. When introduced into ampD1 null or spontaneous mutants, the ampD1 gene rescued the antibiotic-related phenotypes. The AmpD1 amidase from C. violaceum has a unique architecture with an N-terminal acetyltransferase domain. Our work offers new insights into the mechanisms of beta-lactamase-mediated antibiotic resistance and open perspectives to improve the treatment of C. violaceum infections.
- Citations
- 3
- FWCI
- 0.77
- Field percentile
- top 36%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Escape mutations circumvent a tradeoff between resistance to beta-lactams and a beta-lactamase inhibitor
D. Russ, F. Glaser, … R. Kishony·bioRxiv·Aug 9, 2019
- Carbapenem-induced β-lactamase-isoform expression trends in Acinetobacter baumannii
Bogdan M. Benin, Trae Hillyer, … Woo Shik Shin·Scientific ReportsPeer-reviewed·Dec 27, 2024
- Driving factors for beta-lactam resistance gene amplification during de novo resistance evolution in E. coli
Luyuan Nong, Xinwei Liu, … Benno H. ter Kuile·Antimicrobial Agents and ChemotherapyPeer-reviewed·Jul 23, 2025
- Evolution of β-lactamase mediated cefiderocol resistance
Christopher Fröhlich, Vidar Sørum, … Ørjan Samuelsen·Journal of Antimicrobial ChemotherapyPeer-reviewed·Jul 11, 2022
- Progression of ampC amplification during de novo amoxicillin resistance development in E. coli
Luyuan Nong, Martijs J. Jonker, … Benno H. ter Kuile·mBioPeer-reviewed·Dec 20, 2024
- Characterization of a β-lactamase that contributes to intrinsic β-lactam resistance in Clostridioides difficile
B. K. Sandhu, A. N. Edwards, … S. M. McBride·bioRxiv·May 7, 2019